CLRB
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Cellectar Biosciences will present efficacy data from a Phase 2 CLOVER WaM subset analysis of iopofosine I 131 in patients refractory or resistant to BTK inhibitor therapySep 29, 2026
- Cellectar Biosciences reported positive 12-month follow-up data showing durable efficacy of iopofosine I 131May 5, 2026
- Cellectar enrolled the first patient in a Phase 1b trial of CLR 125 for refractory triple-negative breast cancerApr 14, 2026
- Cellectar Biosciences announces EMA confirms eligibility to file for conditional marketing authorization for Iopofosine I 131 as treatment for refractory Waldenstrom macroglobulinemiaOct 6, 2025
- Cellectar Biosciences and ITM enter supply agreement for GMP-grade Actinium-225Sep 11, 2025